Validity and Reliability of the Turkish Version of the London Chest Activity of Daily Living Scale in Obstructive Lung Diseases

Seda Saka1, Sema Savcı2, Ebru Çalış Kütükçü3, Melda Sağlam4, Naciye Vardar Yağılı5, Deniz İnal İnce5, Meral Boşnak Güçlü6, Özge Özalp6, Hülya Ankarı7, Gül Karakaya3, Lütfi Çöplü8

1Department of Physiotherapy and Rehabilitation, Haliç University School of Health Sciences, Istanbul, Turkey
2Department of Physiotherapy and Rehabilitation, Dokuz Eylül University School of Health Sciences, İzmir, Turkey
3Department of Physiotherapy and Rehabilitation, Hacettepe University School of Health Sciences, Ankara, Turkey
4Department of Physiotherapy and Rehabilitation, Gazi University School of Health Sciences, Ankara, Turkey
5Department of Chest Medicine, Hacettepe University School of Medicine, Ankara, Turkey

Cite this article as: Saka S, Savcı S, Çalış Kütükçü E, et al. Validity and Reliability of the Turkish Version of the London Chest Activity of Daily Living Scale in Obstructive Lung Diseases. Turk Thorac J 2020; 21(2): 116-21.

INTRODUCTION

Obstructive lung diseases (OLD) are a common cause of mortality and morbidity throughout the world [1]. Airway obstruction in OLD leads to air trapping, which in turn leads to dyspnea, limitation of activities of daily living (ADL), and a decrease in health-related quality of life (QOL). Systemic inflammation and pulmonary dysfunction are the key features common to OLD. Pulmonary dysfunction and activity limitation due to these conditions bring about skeletal muscle weakness. This results in physical inactivity, restriction of ADL, and subsequent decline in the patients’ QOL [2-5].

The main goal in the treatment of pulmonary diseases is to increase patients’ functional capacity, thereby improving their QOL in ADL. Therefore, determining ADL capacity in pulmonary diseases and the extent of impact on ADL serves as a guide for the development and implementation of interventions to increase functional capacity.

ADL involve caring for oneself and one’s environment, moving in the house and in the community, and engaging in social interaction [6, 7]. Performance of ADL is often evaluated in the clinical setting by asking patients to imitate the activities as they would perform them at home [5]. However, this assessment is not useful in large populations. For this reason, surveys are considered more useful methods for assessing ADL and are commonly used [8].

The currently available tools for specific evaluation of ADL in OLD are insufficient. Tools that assess general functional status are utilized, but the results of this general assessment do not accurately reflect the outcomes of OLD. Other functional status scales, such as the Chronic Respiratory Questionnaire or the Pulmonary Functional Status Scale, are disease-specific but have limited utility and applicability in assessing ADL capacity [9]. One of the most common tools used to detect ADL dysfunction in OLD is the London Chest Activity of Daily Living Scale (LCADL). Several valid translations of the LCADL scale have been completed. This scale is specifically developed to assess the effect of dyspnea on ADL.

RESULTS:
The interobserver reliability of the scale was very high ($r=0.985$, $p<0.050$). Cronbach’s alpha coefficient for total score was 0.976 and intraclass correlation coefficient was 0.953. These results indicate that the Turkish LCADL has high reliability. The correlation between LCADL and 6MWT was moderate ($r=0.503$, $p=0.002$). The LCADL total score was weakly correlated with NHP total score ($r=0.370$, $p=0.040$) and SGRQ total score ($r=0.367$, $p=0.004$).

CONCLUSION: The Turkish version of the LCADL scale is reliable and valid in obstructive lung disease. The LCADL scale will be beneficial in existing pulmonary rehabilitation programs aiming to improve functional status. We believe that using the Turkish LCADL scale as an outcome measure in pulmonary rehabilitation programs will serve as an indicator of rehabilitation efficacy for individual patients.

KEYWORDS: Activities of daily living, London Chest Activities of Daily Living Scale, obstructive lung disease

Received: 20.10.2018 Accepted: 08.03.2019

OBJECTIVES: The London Chest Activity of Daily Living Scale (LCADL) is a simple, useful, and comprehensive measure of dyspnea perception in activities of daily living. This study was conducted to determine the validity and reliability of the Turkish version of the LCADL.

MATERIALS AND METHODS: A total of 64 patients with obstructive lung disease (24 chronic obstructive pulmonary disease, 20 asthma, and 20 bronchiectasis patients) were included. The Turkish LCADL was evaluated for interobserver reliability, test–retest reliability, and criterion validity. Two different observers applied the scale with an interval of 10 minutes to assess interobserver reliability. The second observer applied the scale twice at an interval of 10–15 days to assess test–retest reliability. Criterion validity was assessed using the 6-minute walk test (6MWT), Nottingham Health Profile (NHP), and Saint George Respiratory Questionnaire (SGRQ).

RESULTS: The interobserver reliability of the scale was very high ($r=0.985$, $p<0.050$). Cronbach’s alpha coefficient for total score was 0.976 and intraclass correlation coefficient was 0.953. These results indicate that the Turkish LCADL has high reliability. The correlation between LCADL and 6MWT was moderate ($r=0.503$, $p=0.002$). The LCADL total score was weakly correlated with NHP total score ($r=0.370$, $p=0.040$) and SGRQ total score ($r=0.367$, $p=0.004$).

CONCLUSION: The Turkish version of the LCADL scale is reliable and valid in obstructive lung disease. The LCADL scale will be beneficial in existing pulmonary rehabilitation programs aiming to improve functional status. We believe that using the Turkish LCADL scale as an outcome measure in pulmonary rehabilitation programs will serve as an indicator of rehabilitation efficacy for individual patients.

KEYWORDS: Activities of daily living, London Chest Activities of Daily Living Scale, obstructive lung disease

Received: 20.10.2018 Accepted: 08.03.2019
Moreover, the LCADL is a simple, practical assessment that does not require much time [10]. To date, none of the tools developed to evaluate ADL in pulmonary patients have been shown to be valid and reliable in the Turkish population. Scales that assess general functional status and basic ADL scales are used [11, 12].

The aim of our study was to improve the Turkish version of the LCADL and investigate the reliability and validity of the scale in the evaluation of ADL in patients with OLD.

MATERIALS AND METHODS

Sixty-four patients who were diagnosed with OLD at the Hacettepe University Chest Diseases Department were recruited. Twenty-four of the patients were diagnosed with chronic obstructive pulmonary disease (COPD), 20 with asthma, and 20 with bronchiectasis. Patients who received antibiotic treatment or those with no drug changes within the last 3 weeks, those with orthopedic or neurological diseases, and those who could not understand the questionnaire or other evaluation methods were excluded. The study was approved by the Hacettepe University ethics committee (29.01.2009-LUT 08/50). The scope and purpose of the study was explained to all participants and written informed consent forms were obtained. Physical and sociodemographic data including age, body mass index, symptoms, duration of symptoms, smoking, drug usage, and pulmonary function test results were recorded for all patients.

The LCADL was developed by Garrod et al. [10] as a simple and standardized questionnaire to assess dyspnea resulting from ADL in COPD patients. It consists of a total of 15 items within four domains: personal care (four items), domestic (six items), physical (two items), and leisure (three items). Each item is graded from 0 to 5 with higher scores indicating more difficulty in performing ADL. The scale can be evaluated as the total score, domain scores, and item scores. There is also a single question that assesses to what degree dyspnea perception affects daily life in general. This item is answered by selecting one of following three responses: “a lot,” “a little,” or “not at all” [10].

The LCADL questionnaire was translated to Turkish by two native Turkish speakers proficient in English with permission to translate and use the questionnaires obtained from the authors of the original versions. A synthesis of the two translations was realized to end in a common version. The translation return (from Turkish toward English) was performed by an independent native English speakers proficient in Turkish.

To assess interobserver reliability, the LCADL was applied by two different observers within 10 minutes of one another. For test-retest reliability, the questionnaire was repeated twice by the same observer at an interval of 10-15 days. Three different instruments were used to evaluate criterion validity: the Saint George Respiratory Questionnaire (SGRQ), which is used to assess ADL in patients with OLD; the Nottingham Health Profile (NHP), which is a general health-related QOL questionnaire; and the 6-minute walk test (6MWT), which evaluates functional capacity.

The 6MWT was applied twice on the same day at an interval of 30 minutes to assess exercise capacity. The patient walks at their maximum possible walking speed for 6 minutes in a 30-meter straight corridor [13]. Patients were told before starting the test that they may stop to rest if they feel short of breath during the test and that this time will be included in the test. Oxygen saturation level, heart rate, blood pressure, respiratory rate values, and modified Borg scores for fatigue and dyspnea perception were recorded before and after the test. The 6MWT distance was calculated and recorded as meters. Each patient’s longer distance value from the two tests was used for statistical analysis [14]. Normal ranges for 6MWT distance according to age and sex were used as a reference when interpreting the results [15].

The NHP was used to assess the patients’ overall QOL. It is a general QOL questionnaire designed to measure perceived health problems and the extent to which these problems affect normal daily activities. It consists of 38 items in six dimensions (energy level, pain, physical mobility, emotional reactions, social isolation, and sleep) and can be completed independently by the respondent. A higher score indicates poorer QOL [16].

The SGRQ was used to assess disease-specific QOL. It consists of 76 items and yields a total score and three domain scores (symptom, activity and impact). Each item has its own weighted score. Overall scores range from 0 (no effect on QOL) to a maximum score of 100 (maximum perceived distress); thus, a higher score reflects lower QOL [17].

Sample Size

In validity and reliability studies, the sample size can be calculated as 2-20 patients per question according to Anthoine et al. [18] study. Our study was planned to have four patients for each question in the survey and a total of at least 60 patients.

Statistical Analyses

Statistical analyses were performed using the IBM Statistical Package for the Social Sciences (IBM SPSS Corp.; Armonk, NY, USA) version 22.0 statistical package program for Windows. The data were expressed as mean±standard deviation (SD) for quantitative variables and as percentage (%) for categorical variables. The validity of LCADL was measured.
using correlation between the Turkish version of LCADL and 6MWT, NHP (total and subparameter scores), and SGRQ (total and subparameter scores). The internal consistency of the LCADL was assessed using Cronbach’s α coefficient. The intrarater reliability was measured using the intraclass correlation coefficients (ICC), which indicates the stability of the instrument if ICC ≥0.70. The kappa coefficient (k) was used to assess the reliability of the LCADL scale’s single question item. The probability of error in the statistical analyses was determined as p<0.050.

RESULTS

The demographic and clinical data of the patients in the study are shown in Table 1.

Inter-observer Reliability of the LCADL Scale
For inter-observer reliability of the LCADL, the scale was applied by the first observer and the second observer within 10 minutes on the same day. There was no statistically significant difference between the results obtained by the first and second observers (r=0.985). The observer reliability of the LCADL scale was found to be very high.

Test-Retest Reliability of the LCADL Scale
To assess test-retest reliability of the LCADL, the second observer reapplied the scale after 10-15 days. The means and standard deviations of Test 1 and Test 2 are presented in Table 2. There was no statistically significant difference between the initial test and the retest.

ICC and Cronbach’s alpha coefficient (α) were calculated as measures of reliability. The R², ICC, and 95% CI (confidence interval) values of the LCADL total scores and sub-scores are given in Table 3. Both the LCADL domain scores and total score have high reliability.

The internal consistency and CIs of the tests performed by the first and second observers are shown in Table 4. The comparison between the means of the scores obtained by the first and second observers revealed no statistically significant difference in terms of the total score or a percentage of the total score. The same was true for the comparison of the mean scores obtained by the second observer in the initial test and the retest done 10-15 days later.

LCADL Single Question Item Reliability
Question 16 concerns the extent to which ADL performance is impaired by dyspnea, and patients answer by checking one of three multiple-choice responses: “a lot,” “a little,” or “not at all.” A strong concordance between the two observers (k=0.728; p<0.001) and moderate intrarater agreement (k=0.644; p<0.01) were observed for this question.

LCADL Scale Criterion Validity
There was moderate correlation between 6MWT and LCADL total and self-care scores (r=0.503; p=0.002; r=-0.448; p=0.001, respectively). The relationship between 6MWT and the LCADL total domain and score is shown in Table 5. LCADL total score was weakly correlated with NHP total score (r=0.370; p=0.01); the strongest association was between LCADL total score and NHP energy level score.

---

**Table 1. Demographic and clinical data of the cases**

| Patients (n=64) | Mean±SD |
|----------------|---------|
| Age (years)    | 51.29±13.94 |
| Height (cm)    | 163.42±8.03  |
| Weight (kg)    | 71.57±15.22  |
| BMI (kg/m²)    | 26.72±4.95   |
| Smoking (pack-years) | 22.04±28.45 |
| FEV₁ (%)       | 63.76±24.08  |
| FVC (%)        | 73.53±22.97  |
| FEV₁/FVC (%)   | 72.06±17.86  |
| PEF (%)        | 66.28±27.59  |
| 6MWT distance (m) | 534.77±97.81 |
| MMRC score (0–4) | 1.51±0.77    |

BMI: body mass index; SD: standard deviation; FEV₁: forced expiratory volume in 1 second; FVC: forced vital capacity; PEF: peak expiratory flow; 6MWT: 6-minute walk test; MMRC: modified medical research council

**Table 2. Test–retest reliability of the LCADL scale**

| Test 1 Mean±SD | Test 2 Mean±SD | p     |
|----------------|----------------|-------|
| LCADL self-care | 5.00±1.65     | 5.00±1.62 | 0.256 |
| LCADL domestic   | 4.50±4.79     | 4.50±4.71 | 0.874 |
| LCADL physical activity | 4.00±1.06     | 4.00±1.15 | 0.102 |
| LCADL leisure    | 4.00±1.14     | 4.00±1.11 | 0.376 |
| LCADL total      | 18.10±6.37    | 18.35±6.55 | 0.560 |

Wilcoxon signed rank test. LCADL: London Chest Activity of Daily Life scale; SD: standard deviation

**Table 3. Test–retest correlation analysis of LCADL total and subscores**

| Cronbach’s α | ICC    | 95% CI     |
|--------------|--------|------------|
| LCADL total score | 0.976  | 0.953      | 0.960–0.985 |
| LCADL self-care score | 0.913  | 0.839      | 0.856–0.947 |
| LCADL domestic score | 0.988  | 0.977      | 0.981–0.993 |
| LCADL physical activity score | 0.920  | 0.851      | 0.868–0.951 |
| LCADL leisure score | 0.887  | 0.797      | 0.814–0.931 |

LCADL: London Chest Activity of Daily Life scale; ICC: intraclass correlation coefficient; CI: confidence interval

**Table 4. Intraclass correlation analysis of the LCADL**

| LCADL       | Cronbach’s α | 95% CI     |
|-------------|--------------|------------|
| Observer 1  | 0.705        | 0.594–0.815 |
| Observer 2 - initial test | 0.720        | 0.594–0.815 |
| Observer 2 - retest (10–15 days later) | 0.736        | 0.618–0.826 |

LCADL: London Chest Activity of Daily Life scale; CI: confidence interval
As ability to perform ADL is one of the most important parameters affecting QOL, evaluations of QOL and ADL were also included in our study. NHP and SGRQ were chosen for the QOL questionnaires. Total scores of LCADL and NHP were significantly but weakly correlated. Among the NHP domains, only energy-level score was correlated with LCADL. The presence of primary symptoms such as dyspnea and fatigue, which affect daily life, is expected to correlate with this parameter due to a decrease in energy levels. There was a highly significant moderate correlation between the physical activity domain scores of the two instruments, though LCADL total score was not significantly associated with NHP physical activity domain. This may be a result of low physical activity levels and lack of regular exercise habits. In the LCADL validation studies, only the original study, Garrod et al. [10] used NHP. Although Garrod et al. [10] did not present the correlation results of the sub-parameter scores, the NHP total and LCADL total scores were found to correlate, similar to our study. In other validation studies, the scales used outside the SGRQ were more specific for the disease (such as COPD Assessment Test [CAT], Groningen Activities Restriction Scale [GARS], Modified Medical Research Council [MMRC] Scale) and higher correlation values were obtained [20-22].

The SGRQ is a widely used validation tool in scientific research and was also used as a criterion validation method for the original English version of the LCADL. Since LCADL is a scale for dyspnea perception during activity, the strongest correlation among the SGRQ domains was with the SGRQ activity score. Significant correlations were found between certain SGRQ domains and all domains of the LCADL in our

### Table 5. Relationship between 6MWT distance, NHP, SGRQ, and LCADL scores

|               | LCADL self-care | LCADL domestic | LCADL physical activity | LCADL leisure | LCADL total |
|---------------|----------------|----------------|-------------------------|---------------|-------------|
| **6MWT**      |                 |                |                         |               |             |
| Energy Level  | -0.448**       | 0.001          | -0.375*                 | 0.036         | -0.183      | 0.119       | -0.337** | 0.049 | -0.503** | 0.002 |
| Pain          | 0.355**        | 0.005          | 0.304*                  | 0.018         | 0.276*      | 0.033       | 0.255**  | 0.050 | 0.428**  | 0.001 |
| Emotional reaction | 0.068       | 0.611          | 0.240                  | 0.070         | 0.066       | 0.966       | -0.073   | 0.588 | 0.240    | 0.070 |
| Sleep         | 0.194          | 0.145          | -0.044                  | 0.742         | 0.006       | 0.964       | 0.054    | 0.686 | 0.055    | 0.680 |
| Physical activity | 0.236        | 0.074          | 0.050                  | 0.711         | 0.405*      | 0.002       | 0.259*   | 0.049 | 0.213    | 0.108 |
| Social isolation | 0.236          | 0.075          | 0.076                  | 0.573         | 0.209       | 0.115       | 0.276*   | 0.036 | 0.224    | 0.091 |
| Total         | 0.395**        | 0.002          | 0.193                  | 0.143         | 0.260*      | 0.046       | 0.260*   | 0.047 | 0.370**  | 0.040 |
| **SGRQ**      |                 |                |                         |               |             |
| Symptom       | 0.238          | 0.068          | 0.089                  | 0.499         | 0.269*      | 0.038       | 0.416**  | 0.001 | 0.240    | 0.065 |
| Activity      | 0.402**        | 0.001          | 0.238                  | 0.680         | 0.451**     | 0.000       | 0.395**  | 0.002 | 0.449**  | 0.000 |
| Impact        | 0.284*         | 0.028          | 0.194                  | 0.137         | 0.424**     | 0.001       | 0.503**  | 0.000 | 0.324**  | 0.012 |
| Total         | 0.342**        | 0.008          | 0.199                  | 0.128         | 0.437**     | 0.000       | 0.512**  | 0.000 | 0.367**  | 0.004 |

Spearman correlation analysis *p>0.050, **p>0.010. 6MWT: 6-minute walk test; SGRQ: Saint George Respiratory Questionnaire; LCADL: London Chest Activity of Daily Life scale; NHP: Nottingham Health Profile

(r=0.428, p=0.01). The NHP energy level domain score also correlated with all LCADL domain scores. Correlations between LCADL and the NHP total and domain scores are presented in Table 5.

Weak correlation was observed between LCADL and SGRQ total scores (r=0.367; p=0.004), with the strongest association between LCADL and SGRQ activity domain (r=0.449; p=0.000). The SGRQ symptom and impact domains were more weakly correlated with LCADL (r=0.240; p=0.065 and r=0.324; p=0.012, respectively). Correlations between LCADL and SGRQ total and domain scores are shown in Table 5.

### DISCUSSION

The present study demonstrates that the Turkish version of the LCADL has excellent reliability when applied by different observers and when applied by the same observer at different times. This version also proved to be valid, correlating with established measures of functional exercise capacity and general and health-related QOL. The results obtained with the Turkish version of the LCADL are very similar to those seen in validation studies of the original English version [10].

In inter-observer reliability and test-retest reliability analyses, there were no significant differences between LCADL results obtained by two different observers at 10-minute intervals nor between results obtained by the second observer at two different time points. The ICC of 0.97 for total score indicates excellent reliability. This ICC value was similar to that found by Garrod et al. [10]. Our results show that the Turkish version of the LCADL is reliable.

We used the 6MWT when evaluating the validity of the Turkish LCADL. A strong correlation was found between 6MWT and the LCADL total score in patients with obstructive pulmonary disease. As the patients’ functional capacity decreased, the impact on ADL increased significantly due to dyspnea, in accordance with the literature. Similarly, Brazilian Portuguese, Dutch, and Korean versions were found moderately correlating with their studies [19-21]. Moreover, Garrod et al. [10] demonstrated that patients who scored higher on the LCADL exhibited lower exercise capacity, as determined using the shuttle walk test.
study. However, there was no relationship between SGRQ symptoms, similar to other studies [10,20]. This is to be expected since the LCADL is predominantly concerned with dyspnea whereas the SGRQ investigates other symptoms such as cough, sputum production, and wheeze. The correlations observed in this study are similar to those in other studies using SGRQ for criterion validity [22-24].

An important issue to note regarding the implementation of the LCADL scale is that respondents who have never experienced some activities give these items a score of 0, resulting in a deceptively low total score when they gave 5 points for most other items. This situation was experienced when male subjects answered questions related to the sub-parameter of domestic activities. Since some domestic activities were never experienced by male subjects, 0 responses were given. In order to avoid this problem, items with score 0 are disregarded and the percentage of the total score is used to interpret the scale. The same situation was also reported by Carpes et al. [19]. Another relevant point is that it is not possible to differentiate between exercise-induced dyspnea and allergy- or irritant-induced dyspnea during an activity. For example, it is not clear when using the LCADL whether a person who reports dyspnea during bathing perceives dyspnea due to the shampoo fragrance or overhead activity, or whether someone making the bed perceives dyspnea because of the physical exertion involved or because it introduces dust into the air. Therefore, further research is needed to assess the utility of the LCADL in asthmatic and allergic patients.

Evaluating the sensitivity of the Turkish LCADL to patient responses to therapeutic interventions was not within the scope of this study. Further research is needed in this area. Another limitation of our study is that we did not evaluate correlation with forced expiratory volume in 1 second (FEV<sub>1</sub>) because we included three different disease groups with different respiratory function characteristics. However, Garrod et al. [10] reported a lack of correlation between LCADL and FEV<sub>1</sub> in their study. FEV<sub>1</sub> has been the most common method of assessing disease severity, response to therapy, and (short-term) prognosis in OLD. Yet, the use of FEV<sub>1</sub> as the single best evaluation parameter has been questioned. Therefore, health-related QOL has become an established parameter to assess patients’ subjective experience of the impact of disease. Since there is no strong association between FEV<sub>1</sub> and health-related QOL, both measures seem to highlight different aspects of the disease and therefore provide complementary information on the actual severity of the disease [25].

In conclusion, the Turkish version of the LCADL was found to be valid and reliable for assessing performance of ADL in patients with OLD in the Turkish population. The Turkish LCADL is expected to be clinically useful, as it is short and can be completed by the patients without any assistance. Furthermore, it may serve as a guide for the development and revision of questionnaires and tests specific to Turkish society for validly and reliably evaluating ADL performance.

**Ethics Committee Approval:** Ethics committee approval was received for this study from the ethics committee of Hacettepe University (29.01.2009-LUT 08/50).

**Informed Consent:** Written informed consent was obtained from all participants who participated in this study.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept - S.S., S.Savci., H.A.; Design - S.S., S.Savci., D.I.I.; Supervision - S.S., H.A., D.I.I.; Resources - G.K, L.C.; Materials - G.K., L.C., D.I.I.; Data Collection and/or Processing - S.S., E.C.K., M.S., M.B.G., O.O.; Analysis and/or Interpretation - S.S., E.C.K., M.S., N.V.Y., M.B.G., O.O.; Literature Search - S.S., E.C.K., M.S., N.V.Y.; Writing Manuscript - S.S., E.C.K., M.S., N.V.Y.; Critical Review - S.S., H.A., D.I.I.; Other - G.K., L.C.

**Conflict of Interest:** The authors have no conflicts of interest to declare.

**Financial Disclosure:** The authors declared that this study has received no financial support.

**REFERENCES**

1. Ryu JH, Scanlon PD. Obstructive lung diseases: COPD, asthma, and many imitators. Mayo Clin Proc 2001;76:144-53. [CrossRef]
2. Decramer M, Rennard S, Troosters T, et al. COPD as a lung disease with systemic consequences-clinical impact, mechanisms, and potential for early intervention. COPD 2008;5:235-56. [CrossRef]
3. Conboy-Ellis K. Asthma pathogenesis and management. Nurse Pract 2006;31:24-37. [CrossRef]
4. Ilowite J, Spiegler P, Chawla S. Bronchiectasis: new findings in the pathogenesis and treatment of this disease. Curr Opin Infect Dis 2008;21:163-7. [CrossRef]
5. Velloso M, Jardim JR. Study of energy expenditure during activities of daily living using and not using body position recommended by energy conservation techniques in patients with COPD. Chest 2006;130:126-32. [CrossRef]
6. Leidy NK. Subjective measurement of activity in chronic obstructive pulmonary disease. COPD 2007;4:243-9. [CrossRef]
7. Fricke J, Unsworth C. Occupational therapists’ conceptions of instrumental activities of daily living in relation to evaluation and intervention with older clients. Scand J Occup Ther 1998;5:180-91. [CrossRef]
8. Larson JL. Functional performance and physical activity in chronic obstructive pulmonary disease: theoretical perspectives. COPD 2007;4:237-42. [CrossRef]
9. Tao So C MD. Development and validation of an activities of daily living inventory for the rehabilitation of patients with chronic obstructive pulmonary disease. OTJR 2008;28:149-60. [CrossRef]
10. Garrod R, Bestall JC, Paul EA, et al. Development and validation of a standardized measure of activity of daily living in patients with severe COPD: the London Chest Activity of Daily Living scale (LCADL). Respir Med 2000;94:589-96. [CrossRef]
11. Lareau SC, Carriere-Kohlmann V, Janson-Bjerklie S, Roos PJ. Development and testing of the pulmonary functional status and dyspnea questionnaire (PFSQD). Heart Lung 1994;23:242-50.
12. Nouri E, Lincoln N. An extended activities of daily living scale for stroke patients. Clin Rehab 1987;1:301-5. [CrossRef]
13. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-7. [CrossRef]
14. Wilson RC, Jones P. A comparison of the visual analogue scale and modified Borg scale for the measurement of dyspnoea during exercise. Clin Sci 1989;76:277-82. [CrossRef]
15. Laboratories ACopSICPE. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-7. [CrossRef]
16. Kucukdeveci AA, McKenna SP, Kutlay S, Gursel Y, Whalley D, Arasil T. The development and psychometric assessment of the Turkish version of the Nottingham Health Profile. Int J Rehabil Res 2000;23:31-8. [CrossRef]
17. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991;85(Suppl B):25-37. [CrossRef]

18. Anthoine E, Moret L, Regnault A, et al. Sample size used to validate a scale: a review of publications on newly-developed patient reported outcomes measures. Health Qual Life Outcomes 2014;12:2. [CrossRef]

19. Carpes MF, Mayer AF, Simon KM, Jardim JR, Garrod R. The Brazilian Portuguese version of the London Chest Activity of Daily Living scale for use in patients with chronic obstructive pulmonary disease. J Bras Pneumol 2008;34:143-51. [CrossRef]

20. Klijn P, Legemaat M, Beelen A, Keimpema A, Garrod R, Bergsma M, et al. Validity, reliability, and responsiveness of the Dutch version of the London Chest Activity of Daily Living Scale in Patients With Severe COPD. Medicine (Baltimore) 2015;94:e2191. [CrossRef]

21. Choi JT, Seo JH, Ko MH, Park SH, Kim GW, Won YH. Validation of Korean Version of the London Chest Activity of Daily Living Scale in Patients With Chronic Obstructive Pulmonary Disease. Ann Rehabil Med 2018;42:329-35. [CrossRef]

22. Beaumont M, Couturaud F, Jego F, et al. Validation of the French version of the London Chest Activity of Daily Living scale and the Dyspnea-12 questionnaire. Int J Chron Obstruct Pulmon Dis 2018;13:3999-405. [CrossRef]

23. Klijn P, Legemaat M, Beelen A, et al. Validity, reliability, and responsiveness of the Dutch version of the London Chest Activity of Daily Living Scale in patients with severe COPD. Medicine (Baltimore) 2015;94:e2191. [CrossRef]

24. Pitta F, Probst VS, Kovelis D, et al. Validation of the Portuguese version of the London Chest Activity of Daily Living Scale (LCADL) in chronic obstructive pulmonary disease patients. Rev Port Pneumol 2008;14:27-47. [CrossRef]

25. Hesselink AE, van der Windt DA, Penninx BW, et al. What predicts change in pulmonary function and quality of life in asthma or COPD? J Asthma 2006;43:513-9. [CrossRef]